Fieldpoint Private Securities LLC purchased a new stake in shares of C.R. Bard, Inc. (NYSE:BCR) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 730 shares of the medical instruments supplier’s stock, valued at approximately $234,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in BCR. Farallon Capital Management LLC bought a new position in C.R. Bard during the 2nd quarter valued at $463,101,000. Alpine Associates Management Inc. acquired a new stake in C.R. Bard during the second quarter worth $265,663,000. Pentwater Capital Management LP acquired a new stake in C.R. Bard during the second quarter worth $139,088,000. York Capital Management Global Advisors LLC acquired a new stake in C.R. Bard during the second quarter worth $122,678,000. Finally, CNH Partners LLC acquired a new stake in C.R. Bard during the second quarter worth $116,100,000. 79.35% of the stock is owned by institutional investors and hedge funds.

In other news, Director David M. Barrett sold 3,344 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $327.31, for a total transaction of $1,094,524.64. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Timothy P. Collins sold 8,388 shares of the stock in a transaction on Monday, October 9th. The shares were sold at an average price of $322.00, for a total value of $2,700,936.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 206,637 shares of company stock worth $67,650,121. Company insiders own 0.80% of the company’s stock.

Shares of C.R. Bard, Inc. (BCR) traded up $0.10 on Friday, hitting $332.10. The company had a trading volume of 591,700 shares, compared to its average volume of 661,406. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.72 and a quick ratio of 1.37. C.R. Bard, Inc. has a 1-year low of $216.55 and a 1-year high of $337.73. The firm has a market cap of $24,200.27, a price-to-earnings ratio of 28.67, a PEG ratio of 2.54 and a beta of 0.52.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.96 by $0.06. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. The business had revenue of $989.80 million during the quarter, compared to analyst estimates of $990.64 million. During the same period in the previous year, the firm earned $2.64 EPS. C.R. Bard’s quarterly revenue was up 5.1% compared to the same quarter last year. research analysts anticipate that C.R. Bard, Inc. will post 11.89 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be paid a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.31%. The ex-dividend date of this dividend is Thursday, December 7th. C.R. Bard’s dividend payout ratio is currently 13.70%.

A number of research analysts recently issued reports on BCR shares. Barclays lifted their price target on C.R. Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a report on Monday, November 6th. ValuEngine lowered C.R. Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Cowen restated a “hold” rating and set a $317.00 target price on shares of C.R. Bard in a research report on Friday, November 3rd. Needham & Company LLC restated a “hold” rating on shares of C.R. Bard in a research report on Thursday, October 26th. Finally, Jefferies Group restated a “hold” rating and set a $317.00 target price on shares of C.R. Bard in a research report on Thursday, September 14th. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a strong buy rating to the stock. C.R. Bard has an average rating of “Hold” and an average target price of $303.50.

WARNING: This piece was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/730-shares-in-c-r-bard-inc-bcr-purchased-by-fieldpoint-private-securities-llc/1765672.html.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard and related companies with MarketBeat.com's FREE daily email newsletter.